GI CONNECT expert Prof. Gerald Prager shares an update on what HCPs must consider to achieve a long-term response in advanced colorectal cancer (CRC). Watch the video and download the accompanying slides to understand:

 

  • How to view CRC treatment as a continuum of care

  • What to consider when making treatment decisions

  • Which treatment options are available for CRC patients, 3rd line and beyond

 

After completing this programme, deepen your understanding of this topic with the interactive patient case study Long-term Management of Advanced CRC from Prof. Gerald Prager and Prof. Joleen Hubbard.

 

 

Clinical Takeaways

 

  • Treatment of advanced colorectal cancer (CRC) should be considered as a continuum of care, and patients should be offered as many life-prolonging therapies as possible

  • Decision-making at each stage of therapy should consider patients' suitability and tolerability, tumour biomarkers and prior exposure to chemotherapies and/or targeted agents

  • There are a number of treatment options for CRC patients 3rd line and beyond that should be considered, such as regorafenib, trifluridine/tipiracil as well as consideration of clinical trials and rechallenge with chemotherapy or anti-EGFR

Dr Gerald Prager is an Associate Professor of Medicine, Board Certified for Internal Medicine Board and Certified for Haematology and Medical Oncology. In 2009, he received his M.D. from the University of Vienna. Currently, Dr Prager is Director of the Colorectal Cancer Unit of the Department of Medical Oncology at the Medical University of Vienna. He is also a member of the ESMO 2014 Scientific Committee. The research interest of his lab focuses on (tumour-) angiogenesis via regulation of endothelial cell survival and migration by cell / extracellular-matrix interaction. Through his clinical training in haemato-oncology, he became a member of the sought-after group of medical researches. He achieved his expertise in international renowned labs at University of California, San Diego, the Norris Cancer Center, Los Angeles and the Department of Vascular Biology, Mississippi University for Women (MUW). His work is honoured by 19 international awards and resulted in publications in international highly renowned journals. Dr Prager’s young research group is embedded in an international cancer research campus associated with Medical University of Vienna (MUV).

Assoc. Prof. Gerald Prager has received financial support/sponsorship for research support, consultation, or speaker fees from the following companies:

Amgen, Arcus, Astellas, AstraZeneca, Bayer, BMS, CECOG, Incyte, Lilly, MSD, Merck Serono, Pierre Fabre, Roche, Servier, Takeda

 

 

Programme summary
Watch the video now
Share this programme
This educational programme is supported by an Independent Medical Education Grant from Bayer.
I agree that this educational programme:

Was valuable to me

1/4
Brought to you by
GI CONNECT

GI CONNECT is an initiative of COR2ED, supported by Independent Medical Educational Grants from Bayer and BeiGene Europe.

Meet the experts

Other programmes of interest

Conference update
Oncology 
Oncogene-addicted NSCLC: Highlights from ASCO 2024

The latest non-small cell lung cancer data presented at ASCO

Experts
Prof. Nicolas Girard
  • download Downloadable
    Resources
  • clock 3 MIN
  • calendar Jun 2024

Educational programme supported by an Independent Medical Education grant from Bayer.
Upper lower GI cancer update ASCO 2024 Conference update
Oncology 
Upper and lower GI cancer update from ASCO 2024

GI oncologists review the latest data presented at ASCO 2024

Experts
Dr Samuel J Klempner, Dr Elizabeth Smyth, Prof. Jenny Seligmann, Dr Dominik Modest
  • clock 8 MIN
  • calendar Jun 2024

Educational programme supported by an Independent Medical Education grant from Bayer.
Experts Knowledge Share Video
Oncology Hemato-oncology 
Optimising the management of multiple myeloma in the early relapsed/refractory setting (RRMM)

Medical experts discuss the latest learnings from clinical practice

Experts
Prof. Aurore Perrot, Prof. Hermann Einsele, Assoc. Prof. Karthik Ramasamy, Assoc. Prof. Joshua Richter
  • download Downloadable
    Resources
  • clock 76 MIN
  • calendar Jun 2024

Educational programme supported by an Independent Medical Education grant from Menarini Stemline Oncology.
Conference update

Episode

1

of 4

episode
Oncology 
ASCO 2024 lung cancer highlights

A conference update on lung cancer clinical trial data from ASCO

Experts
Prof. Mark Socinski
  • clock 4 MIN
  • calendar Jun 2024

Conference update

Episode

2

of 4

episode
Oncology 
ASCO 2024 breast cancer highlights

How could the data impact clinical practice?

Experts
Prof. Shaheenah Dawood
  • clock 3 MIN
  • calendar Jun 2024

Conference update

Episode

3

of 4

episode
Oncology 
ASCO 2024 HCC highlights

How could the latest clinical trial data impact the management of hepatocellular carcinoma?

Experts
Prof. Dr Peter R. Galle
  • clock 1 MIN
  • calendar Jun 2024